Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

(2020) Phillip C. C. Liu et al.   PLoS One

Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance

(2020) Melanie A. Krook et al.   BRITISH JOURNAL OF CANCER

Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class

(2020) April Weaver et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors

(2019) Francesco Facchinetti et al.   CLINICAL CANCER RESEARCH

Strategy for Extending Half-life in Drug Design and Its Significance

(2018) Hakan Gunaydin et al.   ACS Medicinal Chemistry Letters

Relevance of Half-Life in Drug Design

(2017) Dennis A. Smith et al.   JOURNAL OF MEDICINAL CHEMISTRY

A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer.

(2017) F. Andre et al.   JOURNAL OF CLINICAL ONCOLOGY

Volume of Distribution in Drug Design

(2015) Dennis A. Smith et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel tactics for designing water-soluble molecules in drug discovery

(2014) Michael A Walker   Expert Opinion on Drug Discovery

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

(2013) Yasuhito Arai et al.   HEPATOLOGY

Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives

(2013) Maria Vittoria Dieci et al.   Cancer Discovery

The significance of acid/base properties in drug discovery

(2012) David T. Manallack et al.   CHEMICAL SOCIETY REVIEWS

Mitigating Heterocycle Metabolism in Drug Discovery

(2012) David J. St. Jean et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks

(2012) Suvi T. M. Orr et al.   JOURNAL OF MEDICINAL CHEMISTRY

Deep understanding of structure–solubility relationship for a diverse set of organic compounds using matched molecular pairs

(2011) Liying Zhang et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Recent advances and novel strategies in pre-clinical formulation development: An overview

(2011) Amit K. Shah et al.   JOURNAL OF CONTROLLED RELEASE

Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry

(2011) Minoru Ishikawa et al.   JOURNAL OF MEDICINAL CHEMISTRY

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

(2010) D. J. Jonker et al.   ANNALS OF ONCOLOGY

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

(2010) J. Weiss et al.   Science Translational Medicine

Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success

(2009) Frank Lovering et al.   JOURNAL OF MEDICINAL CHEMISTRY

The FGF family: biology, pathophysiology and therapy

(2009) Andrew Beenken et al.   NATURE REVIEWS DRUG DISCOVERY

De-regulated FGF receptors as therapeutic targets in cancer

(2009) Victoria Knights et al.   PHARMACOLOGY & THERAPEUTICS

FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival

(2008) K. Kunii et al.   CANCER RESEARCH